{"date":"2025-09-29","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6696-2025-09-29-2117-15mrjco","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2025-09-29","time":"21:17:11","subject":"公告LBS-007急性白血病之第一/二期臨床試驗，獲中國國家藥品監督管理局(NMPA)核准執行","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2025-09-29 21:17，「公告LBS-007急性白血病之第一/二期臨床試驗，獲中國國家藥品監督管理局(NMPA)核准執行」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}